Browse by Poster Presenter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Abdelgawad, Yara

Augusta University
(T1230-02-06) Fostering Innovation and Expanding Institutional Research from Bench to Bedside
Yara Abdelgawad
Favorite
Acharya, Niyati

Nirma University
(M1130-02-06) Anti-Urolithiatic and Diuretic Activities of Ethyl Acetate Fraction of Grewia flavescens Roots
Niyati Acharya
Favorite
Adediran, Emmanuel

Mercer University
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Emmanuel Adediran
Favorite
Adegoke, Ayodeji

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Ayodeji Adegoke
Favorite
Adler, Michael

Chimera Biotec GmbH
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Michael Adler
Favorite
Agrawal, Karan

J&J Innovative Medicine
(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows
Karan Agrawal
Favorite
Ahmad, Aziz

University of Minnesota
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Aziz Ahmad
Favorite
Ahmad, Mohammad Zaki

Najran University
(T0930-01-03) Formulation and Evaluation of Silymarin Proniosomes for Enhanced Solubility, Bioavailability, and Therapeutic Efficacy
Mohammad Zaki Ahmad
Favorite
Aime Fabius, Irabin

South Dakota State University
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Irabin Aime Fabius
Favorite
Akkbik, Mohammed

Qatar University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Mohammed Akkbik
Favorite
Al Qahtani, Noora

Qatar University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Noora Al Qahtani
Favorite
Alani, Adam

Oregon State University
(M1330-01-05) Mitigation of Doxorubicin-Induced Cardiotoxicity and Chemosensitization Using Combination Phytochemicals in Polymeric Micelles
Adam Alani
Favorite
(T0930-01-02) Investigating the Effects of Multi-Drug-Loaded Nanospheres in Enhancing Antitumor Efficacy and Augmenting Immune Response Against Metastatic Melanoma
Adam Alani
Favorite
Alany, Raid

Kingston University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Raid Alany
Favorite
Alavi, Sonia

Univeristy of Illinois Chicago
(M0930-01-04) Macroporous Granular Nanocomposite Hydrogels for Controlled Oligonucleotide Delivery
Sonia Alavi
Favorite
Albarqi, Hassan

Najran University
(T0930-01-03) Formulation and Evaluation of Silymarin Proniosomes for Enhanced Solubility, Bioavailability, and Therapeutic Efficacy
Hassan Albarqi
Favorite
Ali Adib, Sandi

Qatar University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Sandi Ali Adib
Favorite
Alkinani, Ali

Kingston University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Ali Alkinani
Favorite
Allinson, Megan

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Megan Allinson
Favorite
Allison, Jason

Yokogawa Fluence Analytics
(M1030-01-02) Using Novel Light Scattering Technology for Expedited Biologics Stability Assessment: Implications for Successful Development and Manufacturing
Jason Allison
Favorite
Anastasiou, Imogen

Pion Inc.
(M1130-02-08) Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs
Imogen Anastasiou
Favorite
Andrianopoulou, Angeliki

University of Illinois Chicago
(M0930-01-04) Macroporous Granular Nanocomposite Hydrogels for Controlled Oligonucleotide Delivery
Angeliki Andrianopoulou
Favorite
Arnett, Krista

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Krista Arnett
Favorite
Arnold, Joshua

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Joshua Arnold
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Joshua Arnold
Favorite
Arsiccio, Andrea

Coriolis Pharma Research GmbH
(M1230-01-02) Additivity of Transfer Free Energies Enables Description of Complex Protein Formulations in Implicit Solvent Molecular Dynamics Simulations
Andrea Arsiccio
Favorite
(M1430-01-05) Running at the Verge of Collapse in Lyophilization: What is the Impact of the Edge Vial Effect on Protein Stability and Particle Morphology?
Andrea Arsiccio
Favorite
Aubert, Clement

Augusta University
(T1230-02-06) Fostering Innovation and Expanding Institutional Research from Bench to Bedside
Clement Aubert
Favorite
B
Baalasubramanian, Sivasankar

Immunitas Bio
(M0930-02-07) Low Blood Volume Alternative for Monitoring COVID-Specific T-Cell Immunity
Sivasankar Baalasubramanian
Favorite
Baijnath, Himansu

University of KwaZulu-Natal
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Himansu Baijnath
Favorite
Bai, Shuhua

Western New England University
(T1030-01-02) Blueberry-Derived Exosomes as a Natural miRNA Delivery System for the Treatment of Neurodegenerative Diseases
Shuhua Bai
Favorite
Balas, E. Andrew

Augusta University
(T1230-02-06) Fostering Innovation and Expanding Institutional Research from Bench to Bedside
E. Andrew Balas
Favorite
Balasubramanian, Nanda

Bristol-Myers Squibb Company
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Nanda Balasubramanian
Favorite
Balu-Iyer, Sathy

State University of New York at Buffalo, The
(M1430-02-08) Structural Modifications of Phosphatidylserine and Their Impact on Oral Tolerance
Sathy Balu-Iyer
Favorite
Batni, Anjana

Immunitas Bio
(M0930-02-07) Low Blood Volume Alternative for Monitoring COVID-Specific T-Cell Immunity
Anjana Batni
Favorite
Beck, Robert

BioAgilytix
(M1330-02-09) Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples
Robert Beck
Favorite
Belanger, Justine

Cerba Research
(T1130-02-07) Mitigation of the Presence of Crosstalk in an ADA Bridging Assay Using the MSD Platform for the Detection of Antibodies against an Antibody-Drug Conjugate
Justine Belanger
Favorite
Bengtson, Adam

Waters Corporation
(M1030-01-01) Development of Improved Chromatographic Methods for the Separation of Synthetic Peptide Medications and Associated Impurities
Adam Bengtson
Favorite
Bhattacharya, Sanghati

University of Iowa
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Sanghati Bhattacharya
Favorite
Bhavsar, Gaurang

Micro Labs USA, Inc.
(M1130-02-06) Anti-Urolithiatic and Diuretic Activities of Ethyl Acetate Fraction of Grewia flavescens Roots
Gaurang Bhavsar
Favorite
(T1030-01-05) GCMS Analysis of Bioactive Compounds of Extracted Growth Hormone Concentration (Auxin) and Antimicrobial Activity of Pentas lanceolata and Chrysanthemum Morifolium: An Ornamental Flowering Plants
Gaurang Bhavsar
Favorite
Bhela, Siddheshvar

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Siddheshvar Bhela
Favorite
Bigwarfe, Tammy

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Tammy Bigwarfe
Favorite
Bittner, Beate

Roche
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Beate Bittner
Favorite
Blanco, Veronica

Croda Inc.
(M1130-02-09) Alternative Detergents to Triton X-100 for Disrupting Lipid Nanoparticles and Enhancing RNA Encapsulation Quantification in RiboGreen Assay
Veronica Blanco
Favorite
Box, Karl

Pion Inc.
(M1130-02-08) Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs
Karl Box
Favorite
Braham, Scott

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Scott Braham
Favorite
Braithwaite, Christian

BioAgilytix
(M1330-02-09) Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples
Christian Braithwaite
Favorite
(T1030-02-06) Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay
Christian Braithwaite
Favorite
Bramhall, Jessica

University of Georgia
(T1230-01-04) Application of Experimentally Derived Hansen Solubility Parameters to Optimize Amorphous Solid Dispersion Formulation
Jessica Bramhall
Favorite
Brandstetter, Dominik

Coriolis Pharma Research GmbH
(M1230-01-02) Additivity of Transfer Free Energies Enables Description of Complex Protein Formulations in Implicit Solvent Molecular Dynamics Simulations
Dominik Brandstetter
Favorite
(M1430-01-05) Running at the Verge of Collapse in Lyophilization: What is the Impact of the Edge Vial Effect on Protein Stability and Particle Morphology?
Dominik Brandstetter
Favorite
Buckley, Michael

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Michael Buckley
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Michael Buckley
Favorite
Bui, Tam

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Tam Bui
Favorite
C
Caito, Samuel

Husson University
(T1030-01-02) Blueberry-Derived Exosomes as a Natural miRNA Delivery System for the Treatment of Neurodegenerative Diseases
Samuel Caito
Favorite
Caldwell, Jenna

AstraZeneca
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Jenna Caldwell
Favorite
Campbell, Joey

Prolytix
(T1430-02-07) Advancements in Free Heme Analysis: Utilizing a Co-Solvent to Simplify Sample Preparation
Joey Campbell
Favorite
Campellone, Shalyn

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Shalyn Campellone
Favorite
Canham, Spencer

Husson University
(T1030-01-02) Blueberry-Derived Exosomes as a Natural miRNA Delivery System for the Treatment of Neurodegenerative Diseases
Spencer Canham
Favorite
Cao, April

Western Canada High School
(M1230-01-01) Generating Novel Linker Sequences in Antibody-Drug Conjugates with Diffusion Models
April Cao
Favorite
Cao, Yu

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Yu Cao
Favorite
Cataldi, Vince

Oregon State University
(M1330-01-05) Mitigation of Doxorubicin-Induced Cardiotoxicity and Chemosensitization Using Combination Phytochemicals in Polymeric Micelles
Vince Cataldi
Favorite
Chakraborty, Samrat

Oregon State University
(M1330-01-05) Mitigation of Doxorubicin-Induced Cardiotoxicity and Chemosensitization Using Combination Phytochemicals in Polymeric Micelles
Samrat Chakraborty
Favorite
Chakravarty, Amrit

KCAS Bio
(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture
Amrit Chakravarty
Favorite
Chak, Vincent

University at Buffalo
(M1430-02-08) Structural Modifications of Phosphatidylserine and Their Impact on Oral Tolerance
Vincent Chak
Favorite
Challa, Ranadheer Reddy

Quotient Sciences
(T1230-01-01) Mutagenic NDSRI of Citalopram - Critical Structural Evaluation of Carcinogenic Category and Development of a Highly Sensitive LC-MS/MS Method Development for Quantification
Ranadheer Reddy Challa
Favorite
Chang, Irene

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Irene Chang
Favorite
Chaudhary, Ankit

Saraswati Institute of Pharmaceutical Sciences
(M1130-02-06) Anti-Urolithiatic and Diuretic Activities of Ethyl Acetate Fraction of Grewia flavescens Roots
Ankit Chaudhary
Favorite
Cheng, Eric

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Eric Cheng
Favorite
Chen, Jake

University of Alabama at Birmingham
(M1230-01-01) Generating Novel Linker Sequences in Antibody-Drug Conjugates with Diffusion Models
Jake Chen
Favorite
Chen, Quanmin

WuXi Biologics
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Quanmin Chen
Favorite
Chen, Wei

WuXi Biologics
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Wei Chen
Favorite
Chen, Yundi

Binghamton University
(T1430-01-05) Rapid and Precise Detection of Mutations in Extracellular Vesicle DNA Using a Liposome-Based CRISPR-Cas12a System
Yundi Chen
Favorite
Chiu, Mark

Tavotek Biotherapeutics
(M1430-02-06) Clinical Evidence of Safety, Prolonged Half-Life, and Low Immunogenicity of Monoclonal Antibodies TAVO101 and TAVO103 Engineered with Multiple Fc Mutations
Mark Chiu
Favorite
(T1330-02-09) Preliminary Phase 1a Clinical Results of Multispecific Antibody TAVO412 in Patients with Hard-to-Treat Solid Tumors
Mark Chiu
Favorite
Cho, Hea-Young

CHA University
(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy
Hea-Young Cho
Favorite
Cho, Hyunjin

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Hyunjin Cho
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Hyunjin Cho
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Hyunjin Cho
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Hyunjin Cho
Favorite
Choi, Doyoung

SCIEX
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Doyoung Choi
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Doyoung Choi
Favorite
Choi, Go-Wun

CHA University
(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy
Go-Wun Choi
Favorite
Cho, Jong Un

TriOar Inc.
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Jong Un Cho
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Jong Un Cho
Favorite
Cho, Seok-Jin

CHA University
(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy
Seok-Jin Cho
Favorite
Christian, Twinkle

Amgen
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Twinkle Christian
Favorite
Chuh, Josefa

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Josefa Chuh
Favorite
Clegg, Benjamin

Duquesne University
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Benjamin Clegg
Favorite
Clements, Brianna

Waters Corporation
(M1030-01-01) Development of Improved Chromatographic Methods for the Separation of Synthetic Peptide Medications and Associated Impurities
Brianna Clements
Favorite
Coble, Kelly

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Kelly Coble
Favorite
Connor, Robert

Halozyme Therapeutics, Inc.
(T0930-01-05) Preclinical Subcutaneous Injectability and Local Tolerability of an Antibody-Drug Conjugate Delivered with Recombinant Human Hyaluronidase PH20 Using a Handheld High-Volume Auto-Injector
Robert Connor
Favorite
Craig, Kelly

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Kelly Craig
Favorite
Crane, Grant

University of Georgia
(T1230-01-04) Application of Experimentally Derived Hansen Solubility Parameters to Optimize Amorphous Solid Dispersion Formulation
Grant Crane
Favorite
Crouse, Tyler

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Tyler Crouse
Favorite
Cruz, Eric

Celerion
(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Eric Cruz
Favorite
D
Daniels, Austin

Yokogawa Fluid Imaging Technologies
(T1030-01-01) Using Flow Imaging Microscopy to Meet Particulate Matter Standards for Biotherapeutics
Austin Daniels
Favorite
Darling, Ryan

KCAS Bio
(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture
Ryan Darling
Favorite
Davis, Andrew

Eurofins Viracor BioPharma Services
(M1030-02-06) The Importance of Pairing a Matrix with a Nucleic Acid Extraction Approach: Compilation of 66 Bioanalytical PCR (qPCR and dPCR) Validations
Andrew Davis
Favorite
DeGroot, Anne

EpiVax, Inc.
(T1330-02-06) Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis
Anne DeGroot
Favorite
Dela Cruz, Fernando

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Fernando Dela Cruz
Favorite
Desai, Mehul

Enable Injections
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Mehul Desai
Favorite
D, Gayana

Pooja Bhagavat Memorial Mahajana Education Centre
(T1030-01-05) GCMS Analysis of Bioactive Compounds of Extracted Growth Hormone Concentration (Auxin) and Antimicrobial Activity of Pentas lanceolata and Chrysanthemum Morifolium: An Ornamental Flowering Plants
Gayana D
Favorite
Diaz, Manisha

Eurofins Viracor BioPharma Services
(M1030-02-06) The Importance of Pairing a Matrix with a Nucleic Acid Extraction Approach: Compilation of 66 Bioanalytical PCR (qPCR and dPCR) Validations
Manisha Diaz
Favorite
Ding, Jingwen

SCIEX
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Jingwen Ding
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Jingwen Ding
Favorite
Dixit, Anuradha

AbbVie Inc.
(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Anuradha Dixit
Favorite
Dongre, Ashok

Bristol-Myers Squibb Company
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Ashok Dongre
Favorite
D'souza, Bernadette

Samford University
(M1030-01-05) Evaluating the Immunomodulatory Efficacy of an Ethanolic Spray-Dried Extract of Spirulina
Bernadette D'souza
Favorite
D'Souza, Marissa

University of Michigan Medical Center
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Marissa D'Souza
Favorite
Dufield, Dawn

KCAS Bio
(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture
Dawn Dufield
Favorite
Dutta, Kingshuk

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Kingshuk Dutta
Favorite
E
Empey, Kerry

University of Pittsburgh
(M1230-01-03) Pegylation Enhanced Mucin Penetration of Biotinylated PLGA Nanoparticles
Kerry Empey
Favorite
Engstrom, Johan

Gyros Protein Technologies
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Johan Engstrom
Favorite
Esfandiary, Reza

AstraZeneca
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Reza Esfandiary
Favorite
F
Fan, Yong

Allegheny Health Network
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Yong Fan
Favorite
Farnsworth, Nikki L

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Nikki L Farnsworth
Favorite
Farrell, Christopher

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Christopher Farrell
Favorite
Fasiku, Victoria

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Victoria Fasiku
Favorite
Faya, Mbuso

University of KwaZulu-Natal
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Mbuso Faya
Favorite
Feng, Wen

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Wen Feng
Favorite
Ferguson, Alex

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Alex Ferguson
Favorite
Ferguson, Amarae

Mercer University
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Amarae Ferguson
Favorite
Ferris, Smantha

Waters Corporation
(T1330-02-07) Quantitative Bioanalysis of Large Peptides and Proteins: Case Study of GLP-1 Receptor Agonist Semaglutide in Plasma
Smantha Ferris
Favorite
Finn, M.G.

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
M.G. Finn
Favorite
Fischer, James

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
James Fischer
Favorite
Fisher, Richard

Orion Therapeutics, Inc.
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Richard Fisher
Favorite
Forsström, Daniel

Gyros Protein Technologies
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Daniel Forsström
Favorite
Forster, Seth

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Seth Forster
Favorite
Forte, Andre

Cerba Research
(T1130-02-07) Mitigation of the Presence of Crosstalk in an ADA Bridging Assay Using the MSD Platform for the Detection of Antibodies against an Antibody-Drug Conjugate
Andre Forte
Favorite
Fox, Chris

Gyros Protein Technologies
(M1330-02-08) Analysis of Pre-existing Anti-AAV Antibodies Using a Novel Nanoliter Total Antibody Assay: A Serotype-Independent Approach
Chris Fox
Favorite
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Chris Fox
Favorite
Freeman, Michael

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Michael Freeman
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Michael Freeman
Favorite
French, Daniel

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Daniel French
Favorite
Fu, Wenxian

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Wenxian Fu
Favorite
G
G. Johansen, Chelsea

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Chelsea G. Johansen
Favorite
Gallegos, Austin

AstraZeneca
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Austin Gallegos
Favorite
Gambardella, Janice

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Janice Gambardella
Favorite
Gao, Chan

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Chan Gao
Favorite
Gaudet, Suzanne

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Suzanne Gaudet
Favorite
Gawalt, Ellan

Duquesne University
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Ellan Gawalt
Favorite
Gemeinhart, Richard

University of Illinois Chicago
(M0930-01-04) Macroporous Granular Nanocomposite Hydrogels for Controlled Oligonucleotide Delivery
Richard Gemeinhart
Favorite
Ghosh, Santaneel

Southeast Missouri State University
(M0930-01-03) Antiproliferative Effects of Low Level Light-Low Dose Magnetic Nanoparticle Exposure on Human Umbilical Vein Endothelial Cells
Santaneel Ghosh
Favorite
Ghugari, Rahul

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Rahul Ghugari
Favorite
Goihberg, Polina

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Polina Goihberg
Favorite
Gomes, Conor

Pion Inc.
(M1130-02-08) Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs
Conor Gomes
Favorite
Goodall, Carlie

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Carlie Goodall
Favorite
Goodman, Joanne

Celerion
(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Joanne Goodman
Favorite
Gopal, Kausy

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Kausy Gopal
Favorite
Grafelman, Daryl

Celerion
(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Daryl Grafelman
Favorite
Grall, Franck

BioAgilytix
(M1330-02-09) Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples
Franck Grall
Favorite
(T1030-02-06) Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay
Franck Grall
Favorite
Grandas, Oscar

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Oscar Grandas
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Oscar Grandas
Favorite
Grimsley, Lauren

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Lauren Grimsley
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Lauren Grimsley
Favorite
Grosskopf, Abigail

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Abigail Grosskopf
Favorite
Gulianello, Michael

Sanofi
(T1130-02-08) Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers
Michael Gulianello
Favorite
Guo, Jeremy

WuXi Biologics
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Jeremy Guo
Favorite
Guo, Jinglong

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Jinglong Guo
Favorite
Gupta, Swati

AbbVie Inc.
(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Swati Gupta
Favorite
Gurumoorthy, Viswanathan

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Viswanathan Gurumoorthy
Favorite
Gurvich, Vadim J.

University of Minnesota
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Vadim J. Gurvich
Favorite
H
Hagos, Patricia

Gyros Protein Technologies
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Patricia Hagos
Favorite
Han, Chao

Tavotek Biotherapeutics
(M1430-02-06) Clinical Evidence of Safety, Prolonged Half-Life, and Low Immunogenicity of Monoclonal Antibodies TAVO101 and TAVO103 Engineered with Multiple Fc Mutations
Chao Han
Favorite
(T1330-02-09) Preliminary Phase 1a Clinical Results of Multispecific Antibody TAVO412 in Patients with Hard-to-Treat Solid Tumors
Chao Han
Favorite
Hardcastle, Chris

Aliri Bioanalysis
(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows
Chris Hardcastle
Favorite
Hedström, Kira

Gyros Protein Technologies
(M1330-02-08) Analysis of Pre-existing Anti-AAV Antibodies Using a Novel Nanoliter Total Antibody Assay: A Serotype-Independent Approach
Kira Hedström
Favorite
Hejmady, Siddhanth

University of Iowa
(M1030-01-04) Impact of Handling and Transfer on Aggregation of a Trastuzumab Biosimilar in an In-Use Study
Siddhanth Hejmady
Favorite
Hickey, James C.

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
James C. Hickey
Favorite
Hong, Paula

Waters Corporation
(M0930-01-05) Modernization of Compendial Size-Exclusion Chromatography Aggregation Analysis Methods in Compliance with Updates to USP General Chapter < 129 >
Paula Hong
Favorite
Houston, Erin

Eurofins PSS Insourcing Solutions
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Erin Houston
Favorite
Howe, Lisa

EpiVax, Inc.
(T1330-02-06) Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis
Lisa Howe
Favorite
Hu, Qiaobin

Croda, Inc.
(M1130-02-09) Alternative Detergents to Triton X-100 for Disrupting Lipid Nanoparticles and Enhancing RNA Encapsulation Quantification in RiboGreen Assay
Qiaobin Hu
Favorite
Huynh, Jason

AbbVie Inc.
(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Jason Huynh
Favorite
Hwang, Jasmine (Jimin)

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
Jasmine (Jimin) Hwang
Favorite
Hwang, Sangsoo

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Sangsoo Hwang
Favorite
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Sangsoo Hwang
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Sangsoo Hwang
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Sangsoo Hwang
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Sangsoo Hwang
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Sangsoo Hwang
Favorite
Hwang, Sarah

Sanofi
(T1130-02-08) Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers
Sarah Hwang
Favorite
I
Ike, Blessing

University of KwaZulu-Natal
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Blessing Ike
Favorite
Iyer, Ashvin

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Ashvin Iyer
Favorite
J
Jatyan, Reena

Binghamton University
(M1230-01-04) Engineering ‘Eat Me’ Signals for LNPs to Enhance mRNA Cancer Vaccination
Reena Jatyan
Favorite
Jawa, Rayan

University of Pennsylvania
(M0930-02-07) Low Blood Volume Alternative for Monitoring COVID-Specific T-Cell Immunity
Rayan Jawa
Favorite
Jawa, Vibha

Bristol-Myers Squibb Company
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Vibha Jawa
Favorite
Jones, Jeff

Cullinan Therapeutics
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Jeff Jones
Favorite
K
K M, Preethushree

Pooja Bhagavat Memorial Mahajana Education Centre
(T1030-01-05) GCMS Analysis of Bioactive Compounds of Extracted Growth Hormone Concentration (Auxin) and Antimicrobial Activity of Pentas lanceolata and Chrysanthemum Morifolium: An Ornamental Flowering Plants
Preethushree K M
Favorite
K.C., Remant

University of Alberta
(M1430-01-04) Implementing siRNA Therapy Targeted at MLL-AF4 in Acute Lymphoblastic Leukemia
Remant K.C.
Favorite
Kadavil, Hana

Qatar University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Hana Kadavil
Favorite
Kalpana, Marjina Akter

University of Nebraska Medical Center
(T1030-01-04) Development of Polymer-Based miRNA Delivery System for CXCR4 Inhibition and miR155 Inhibition in Target Cells in the Liver to Treat Alcohol-Associated Liver Disease
Marjina Akter Kalpana
Favorite
Kandalam, Umadevi

Woody L. Hunt School of Dental Medicine
(T0930-02-06) Co-culture of Pre-programmed Angiogenic and Osteogenic Gingival Stem Cells Enhances Osteogenesis
Umadevi Kandalam
Favorite
Kandel, Sagar

Southeast Missouri State University
(M0930-01-03) Antiproliferative Effects of Low Level Light-Low Dose Magnetic Nanoparticle Exposure on Human Umbilical Vein Endothelial Cells
Sagar Kandel
Favorite
Kang, David

Halozyme Therapeutics, Inc.
(T0930-01-05) Preclinical Subcutaneous Injectability and Local Tolerability of an Antibody-Drug Conjugate Delivered with Recombinant Human Hyaluronidase PH20 Using a Handheld High-Volume Auto-Injector
David Kang
Favorite
Kang, Dong Wook

College of Pharmacy, CHA University
(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy
Dong Wook Kang
Favorite
Kaplan, Gilad

AstraZeneca
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Gilad Kaplan
Favorite
Kelly, Ryan

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Ryan Kelly
Favorite
Khera, Eshita

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Eshita Khera
Favorite
Kim, Daniel

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Daniel Kim
Favorite
Kim, Do Hyeon

TriOar Inc.
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Do Hyeon Kim
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Do Hyeon Kim
Favorite
Kim, Ju Hee

CHA University
(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy
Ju Hee Kim
Favorite
Kim, Seoyeon

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Seoyeon Kim
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Seoyeon Kim
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Seoyeon Kim
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Seoyeon Kim
Favorite
Kindhart, Richard

Merck & Co., Inc.
(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay
Richard Kindhart
Favorite
King, Lindsay

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Lindsay King
Favorite
Kirkpatrick, Stacy

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Stacy Kirkpatrick
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Stacy Kirkpatrick
Favorite
Kolomiyets, Anton

BioAgilytix
(T1030-02-06) Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay
Anton Kolomiyets
Favorite
Kolpek, Daniel

University of Kentucky
(M0930-02-06) Investigations into the Effects of Protein Corona Formation on Novel Polymeric Nanoparticle Systems
Daniel Kolpek
Favorite
Konovalov, Andrey

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Andrey Konovalov
Favorite
Koobatian, Maxwell

Crinetics
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Maxwell Koobatian
Favorite
Kopcho, Noah

Gyros Protein Technologies
(M1330-02-08) Analysis of Pre-existing Anti-AAV Antibodies Using a Novel Nanoliter Total Antibody Assay: A Serotype-Independent Approach
Noah Kopcho
Favorite
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Noah Kopcho
Favorite
Kotowski, Don

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Don Kotowski
Favorite
Kuebler, Sigrid

Yokogawa Fluid Imaging Technologies
(T1030-01-01) Using Flow Imaging Microscopy to Meet Particulate Matter Standards for Biotherapeutics
Sigrid Kuebler
Favorite
Kumari, Neha

University of Nebraska Medical Center
(T1030-01-04) Development of Polymer-Based miRNA Delivery System for CXCR4 Inhibition and miR155 Inhibition in Target Cells in the Liver to Treat Alcohol-Associated Liver Disease
Neha Kumari
Favorite
Kumar, Naveen

Surana College Autonomus
(T1030-01-05) GCMS Analysis of Bioactive Compounds of Extracted Growth Hormone Concentration (Auxin) and Antimicrobial Activity of Pentas lanceolata and Chrysanthemum Morifolium: An Ornamental Flowering Plants
Naveen Kumar
Favorite
Kumar, Ramya

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Ramya Kumar
Favorite
L
Lahiri, Priyanka

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Priyanka Lahiri
Favorite
Lakshmi, Muthu

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Muthu Lakshmi
Favorite
Langlois, Marie-Pierre

Syneos Health
(T1230-02-07) Highly Specific Bridging ECL Assay for Small Peptide Drug Modalities and Their Use as an Alternative to a Direct ELISA Approach
Marie-Pierre Langlois
Favorite
Lawson, Jessica L.

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Jessica L. Lawson
Favorite
Laxmanan, Sreenivas

BioAgilytix
(T1030-02-06) Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay
Sreenivas Laxmanan
Favorite
Le, Amy

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Amy Le
Favorite
Lee, Byeong-jun

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Byeong-jun Lee
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Byeong-jun Lee
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Byeong-jun Lee
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Byeong-jun Lee
Favorite
Lee, Dong Hun

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Dong Hun Lee
Favorite
(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay
Dong Hun Lee
Favorite
Lee, Dong Yun

Hanyang University / Elixir Pharmatech
(T1330-01-01) ROS-Responsive Mucoadhesive Pro-drug with Mesalazine for Curing Inflammatory Bowel Disease
Dong Yun Lee
Favorite
Lee, Juwon

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Juwon Lee
Favorite
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Juwon Lee
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Juwon Lee
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Juwon Lee
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Juwon Lee
Favorite
Lee, Luke P.

Harvard Medical School
(T1430-01-05) Rapid and Precise Detection of Mutations in Extracellular Vesicle DNA Using a Liposome-Based CRISPR-Cas12a System
Luke P. Lee
Favorite
Lee, Meelim

Novartis Biomedical Research
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Meelim Lee
Favorite
Lefevre, Tyler

AstraZeneca
(T1030-02-07) Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Tyler Lefevre
Favorite
Lepoitevin, Mathilde

Institut des Matériaux Poreux de Paris
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Mathilde Lepoitevin
Favorite
Liang, Yingkai

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Yingkai Liang
Favorite
Li, Jing

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Jing Li
Favorite
Li, Li

Resolian Inc.
(T1430-02-08) A Sensitive, Specific and High-throughput Assay to Quantify an Oligonucleotide Therapeutics in Monkey Liver using Stem‑Loop RT-qPCR Platform
Li Li
Favorite
Lim Soo, Patrick

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Patrick Lim Soo
Favorite
Lim, Jeong-hyeon

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Jeong-hyeon Lim
Favorite
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Jeong-hyeon Lim
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Jeong-hyeon Lim
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Jeong-hyeon Lim
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Jeong-hyeon Lim
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Jeong-hyeon Lim
Favorite
Lin, Yu-Jiun

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Yu-Jiun Lin
Favorite
Liu, Aihua

Resolian Inc.
(T1430-02-08) A Sensitive, Specific and High-throughput Assay to Quantify an Oligonucleotide Therapeutics in Monkey Liver using Stem‑Loop RT-qPCR Platform
Aihua Liu
Favorite
Liu, Shiliang

Resolian Inc.
(T1430-02-08) A Sensitive, Specific and High-throughput Assay to Quantify an Oligonucleotide Therapeutics in Monkey Liver using Stem‑Loop RT-qPCR Platform
Shiliang Liu
Favorite
Liu, Wen

Allegheny Health Network
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Wen Liu
Favorite
Li, Xiyue

Duquesne University
(M1230-01-03) Pegylation Enhanced Mucin Penetration of Biotinylated PLGA Nanoparticles
Xiyue Li
Favorite
Locklin, Jason

University of Georgia
(T1230-01-04) Application of Experimentally Derived Hansen Solubility Parameters to Optimize Amorphous Solid Dispersion Formulation
Jason Locklin
Favorite
Lopez, Diariza

Woody L. Hunt School of Dental Medicine
(T0930-02-06) Co-culture of Pre-programmed Angiogenic and Osteogenic Gingival Stem Cells Enhances Osteogenesis
Diariza Lopez
Favorite
Löthberg, Frida

Gyros Protein Technologies
(M1330-02-08) Analysis of Pre-existing Anti-AAV Antibodies Using a Novel Nanoliter Total Antibody Assay: A Serotype-Independent Approach
Frida Löthberg
Favorite
(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow
Frida Löthberg
Favorite
Lucero, Sujey

Texas Tech University Health Sciences Center
(T0930-02-06) Co-culture of Pre-programmed Angiogenic and Osteogenic Gingival Stem Cells Enhances Osteogenesis
Sujey Lucero
Favorite
Luo, Linlin

Merck
(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay
Linlin Luo
Favorite
M
Mack, Scott

SCIEX
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Scott Mack
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Scott Mack
Favorite
MacNichol, Paul

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Paul MacNichol
Favorite
Mahek, Gulani

Mercer University
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Gulani Mahek
Favorite
Maijorovaite, Zaneta

Teva Pharmaceutical Industries Ltd.
(T1030-01-03) ATR-FTIR Spectroscopy as an Orthogonal Method for Secondary Structure Characterization of Monoclonal Antibodies Under Thermal Stress
Zaneta Maijorovaite
Favorite
Mamelak, Dan

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Dan Mamelak
Favorite
Mao, Yan

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Yan Mao
Favorite
Marshall, Lilly

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Lilly Marshall
Favorite
Martyniak, Kari

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Kari Martyniak
Favorite
Mashinini, Lwazi

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Lwazi Mashinini
Favorite
Mattei, Aimee

EpiVax, Inc.
(T1330-02-06) Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis
Aimee Mattei
Favorite
Ma, Zitao

Binghamton University
(M1230-01-04) Engineering ‘Eat Me’ Signals for LNPs to Enhance mRNA Cancer Vaccination
Zitao Ma
Favorite
McGrath, Caleb

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Caleb McGrath
Favorite
McMaster, Kelly-Anne

Samford University
(M1030-01-05) Evaluating the Immunomodulatory Efficacy of an Ethanolic Spray-Dried Extract of Spirulina
Kelly-Anne McMaster
Favorite
McNally, Michael

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Michael McNally
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Michael McNally
Favorite
McNevin, Michael

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Michael McNevin
Favorite
Mei, Kuo-Ching

State University of New York at Binghamton
(M1230-01-04) Engineering ‘Eat Me’ Signals for LNPs to Enhance mRNA Cancer Vaccination
Kuo-Ching Mei
Favorite
Meng, Fei

Frontage Laboratories, Inc.
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Fei Meng
Favorite
Meng, Wilson

Duquesne University
(M1230-01-03) Pegylation Enhanced Mucin Penetration of Biotinylated PLGA Nanoparticles
Wilson Meng
Favorite
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Wilson Meng
Favorite
Menon, Sreejit

Croda Inc.
(M1130-02-09) Alternative Detergents to Triton X-100 for Disrupting Lipid Nanoparticles and Enhancing RNA Encapsulation Quantification in RiboGreen Assay
Sreejit Menon
Favorite
Menzen, Tim

Coriolis Pharma Research GmbH
(M1230-01-02) Additivity of Transfer Free Energies Enables Description of Complex Protein Formulations in Implicit Solvent Molecular Dynamics Simulations
Tim Menzen
Favorite
(M1430-01-05) Running at the Verge of Collapse in Lyophilization: What is the Impact of the Edge Vial Effect on Protein Stability and Particle Morphology?
Tim Menzen
Favorite
Mickey, Kristen

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Kristen Mickey
Favorite
Mitra, Somesree

University of Texas Southwestern Medical Center
(M0930-01-03) Antiproliferative Effects of Low Level Light-Low Dose Magnetic Nanoparticle Exposure on Human Umbilical Vein Endothelial Cells
Somesree Mitra
Favorite
Mohana Sundaram, Soumya

Celerion
(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Soumya Mohana Sundaram
Favorite
Moore, Tyler

Celerion
(M1030-02-09) Advancing Peripheral Blood Mononuclear Cells Isolation for ELISPOT Analysis: Time Is Critical
Tyler Moore
Favorite
Moreau, Gautier

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Gautier Moreau
Favorite
Mountain, Deidra

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Deidra Mountain
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Deidra Mountain
Favorite
Mukherjee, Lipi

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Lipi Mukherjee
Favorite
Murray, Kimberly

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Kimberly Murray
Favorite
Muzumdar, Isha

University of Iowa
(M1030-01-04) Impact of Handling and Transfer on Aggregation of a Trastuzumab Biosimilar in an In-Use Study
Isha Muzumdar
Favorite
N
Nanayakkara, Malsha

Southeast Missouri State University
(M0930-01-03) Antiproliferative Effects of Low Level Light-Low Dose Magnetic Nanoparticle Exposure on Human Umbilical Vein Endothelial Cells
Malsha Nanayakkara
Favorite
Narayanan, Srividya

Northeatern University
(T1230-01-02) Rapid Diagnostics Redefined: The Power of Point-of-Care Testing
Srividya Narayanan
Favorite
Narula, Jatin

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Jatin Narula
Favorite
Nasrullah, Mohammad

University of Alberta
(M1430-01-04) Implementing siRNA Therapy Targeted at MLL-AF4 in Acute Lymphoblastic Leukemia
Mohammad Nasrullah
Favorite
Nejadnik, Reza

University of Iowa
(M1030-01-04) Impact of Handling and Transfer on Aggregation of a Trastuzumab Biosimilar in an In-Use Study
Reza Nejadnik
Favorite
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Reza Nejadnik
Favorite
Nekoroski, Tara

Halozyme Therapeutics, Inc.
(T0930-01-05) Preclinical Subcutaneous Injectability and Local Tolerability of an Antibody-Drug Conjugate Delivered with Recombinant Human Hyaluronidase PH20 Using a Handheld High-Volume Auto-Injector
Tara Nekoroski
Favorite
Neubert, Hendrick

Pfizer Inc.
(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Hendrick Neubert
Favorite
Nie, Haichen

Teva Pharmaceutical Industries Ltd.
(T1030-01-03) ATR-FTIR Spectroscopy as an Orthogonal Method for Secondary Structure Characterization of Monoclonal Antibodies Under Thermal Stress
Haichen Nie
Favorite
Nolan, Matthew

Prolytix
(T1430-02-07) Advancements in Free Heme Analysis: Utilizing a Co-Solvent to Simplify Sample Preparation
Matthew Nolan
Favorite
Nwabuife, Joshua

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Joshua Nwabuife
Favorite
O
Okamoto, Emily

AbbVie Inc.
(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Emily Okamoto
Favorite
Okoh, Grace

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Grace Okoh
Favorite
Ortiz, Jessica

Moderna Therapeutics
(T0930-02-07) Comparison of Various Methods to Quantitate mRNA from LNP-mRNA-ABC in Human Serum
Jessica Ortiz
Favorite
Osakwe, Adaeze

University of Georgia
(T1230-01-04) Application of Experimentally Derived Hansen Solubility Parameters to Optimize Amorphous Solid Dispersion Formulation
Adaeze Osakwe
Favorite
Ostrowski, Maggie

SCIEX
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Maggie Ostrowski
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Maggie Ostrowski
Favorite
Ostrowski, Sarah

University of Pittsburgh
(M1230-01-03) Pegylation Enhanced Mucin Penetration of Biotinylated PLGA Nanoparticles
Sarah Ostrowski
Favorite
Oupicky, David

University of Nebraska Medical Center
(T1030-01-04) Development of Polymer-Based miRNA Delivery System for CXCR4 Inhibition and miR155 Inhibition in Target Cells in the Liver to Treat Alcohol-Associated Liver Disease
David Oupicky
Favorite
P
Pabit, Suzette

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Suzette Pabit
Favorite
Pack, Daniel

University of Kentucky
(M0930-02-06) Investigations into the Effects of Protein Corona Formation on Novel Polymeric Nanoparticle Systems
Daniel Pack
Favorite
Palmer, Rachel

Sanofi
(T1130-02-08) Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers
Rachel Palmer
Favorite
Parikh, Maulik

Alnylam Pharmaceuticals Inc.
(T1430-01-03) Importance of Early-Stage Process Design Space Assessment for Lipid Nanoparticles (LNP) Technology Transfer
Maulik Parikh
Favorite
Park, Jonghyuck

University of Kentucky
(M0930-02-06) Investigations into the Effects of Protein Corona Formation on Novel Polymeric Nanoparticle Systems
Jonghyuck Park
Favorite
Park, Jungsoo

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Jungsoo Park
Favorite
Park, Kyunga

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Kyunga Park
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Kyunga Park
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Kyunga Park
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Kyunga Park
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Kyunga Park
Favorite
Park, Seo-jin

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Seo-jin Park
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Seo-jin Park
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Seo-jin Park
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Seo-jin Park
Favorite
Park, Su Ho

TriOar Inc.
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Su Ho Park
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Su Ho Park
Favorite
Parlak, Zehra

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Zehra Parlak
Favorite
Pasupuleti, Dedeepya

Mercer University
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Dedeepya Pasupuleti
Favorite
Patel, Jennifer

Moderna Therapeutics
(T0930-02-07) Comparison of Various Methods to Quantitate mRNA from LNP-mRNA-ABC in Human Serum
Jennifer Patel
Favorite
Patel, Rajanikant

Granules Pharmaceutical Inc.
(M1230-01-05) Comparison of Commonly Used Hydrophilic Polymers for Matrix Tablet Formulation and Evaluation of Drug Release in Hydro-Alcoholic Media
Rajanikant Patel
Favorite
Patel, Vaibhavkumar

Saraswati Institute of Pharmaceutical Sciences
(M1130-02-06) Anti-Urolithiatic and Diuretic Activities of Ethyl Acetate Fraction of Grewia flavescens Roots
Vaibhavkumar Patel
Favorite
Pennock, Nathan

Oregon Health and Science University
(T0930-01-02) Investigating the Effects of Multi-Drug-Loaded Nanospheres in Enhancing Antitumor Efficacy and Augmenting Immune Response Against Metastatic Melanoma
Nathan Pennock
Favorite
Pennucci, Jason

Moderna Therapeutics
(T0930-02-07) Comparison of Various Methods to Quantitate mRNA from LNP-mRNA-ABC in Human Serum
Jason Pennucci
Favorite
Pilaev, Martin

Syneos Health
(T1230-02-07) Highly Specific Bridging ECL Assay for Small Peptide Drug Modalities and Their Use as an Alternative to a Direct ELISA Approach
Martin Pilaev
Favorite
Pillai, Medha

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
Medha Pillai
Favorite
Plumb, Robert

Waters Corporation
(M1330-02-07) Investigating Off Target Pharmacology and Metabolism of Methapyrilene Using Metabolomics, Lipidomics, and MS Imaging: A Case Study
Robert Plumb
Favorite
(T1330-02-07) Quantitative Bioanalysis of Large Peptides and Proteins: Case Study of GLP-1 Receptor Agonist Semaglutide in Plasma
Robert Plumb
Favorite
Polli, Ryan

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Ryan Polli
Favorite
Puri, Riya

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Riya Puri
Favorite
Q
Quach, Vianna

Northeastern University
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Vianna Quach
Favorite
R
Radinov, Roumen

Alnylam Pharmaceuticals Inc.
(T1430-01-03) Importance of Early-Stage Process Design Space Assessment for Lipid Nanoparticles (LNP) Technology Transfer
Roumen Radinov
Favorite
Radmall, Kyler

Aliri Bioanalysis
(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows
Kyler Radmall
Favorite
Raha, Nancy

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Nancy Raha
Favorite
Rahman, Md Mofizur

Binghamton University
(T1430-01-05) Rapid and Precise Detection of Mutations in Extracellular Vesicle DNA Using a Liposome-Based CRISPR-Cas12a System
Md Mofizur Rahman
Favorite
Rahman, Omar

Enable Injections
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Omar Rahman
Favorite
Rainville, Paul D.

Waters Corporation
(M1030-01-01) Development of Improved Chromatographic Methods for the Separation of Synthetic Peptide Medications and Associated Impurities
Paul D. Rainville
Favorite
Rajagopalan, Deepa

45 Management LLC
(T1430-01-02) Insights from Drug Development Experts: Surveying Challenges and Outcomes for Large-Volume Subcutaneous Oncology Drugs
Deepa Rajagopalan
Favorite
Rathore, Anurag

IITD
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Anurag Rathore
Favorite
Ray, Arpita

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Arpita Ray
Favorite
Reddy, Gayathri Aparnasai

Duquesne University
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Gayathri Aparnasai Reddy
Favorite
Reed, Corey

Waters Corporation
(M0930-01-05) Modernization of Compendial Size-Exclusion Chromatography Aggregation Analysis Methods in Compliance with Updates to USP General Chapter < 129 >
Corey Reed
Favorite
Refaat, Hesham

University of Iowa
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Hesham Refaat
Favorite
Reineke, Joshua

South Dakota State University
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Joshua Reineke
Favorite
Ren, Steven

WuXi Biologics US
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Steven Ren
Favorite
Reynolds, Anh

Bristol-Myers Squibb Company
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Anh Reynolds
Favorite
Rizvi, Syed

Oregon State University
(M1330-01-05) Mitigation of Doxorubicin-Induced Cardiotoxicity and Chemosensitization Using Combination Phytochemicals in Polymeric Micelles
Syed Rizvi
Favorite
(T0930-01-02) Investigating the Effects of Multi-Drug-Loaded Nanospheres in Enhancing Antitumor Efficacy and Augmenting Immune Response Against Metastatic Melanoma
Syed Rizvi
Favorite
Roadcap, Brad

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Brad Roadcap
Favorite
Robbins, David

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
David Robbins
Favorite
Roberge, Martin

Cerba Research
(T1130-02-07) Mitigation of the Presence of Crosstalk in an ADA Bridging Assay Using the MSD Platform for the Detection of Antibodies against an Antibody-Drug Conjugate
Martin Roberge
Favorite
Ross, Alexander

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Alexander Ross
Favorite
Rowe, Josh

AbbVie Inc.
(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Josh Rowe
Favorite
S
Salinger, Ari

Bristol-Myers Squibb Company
(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach
Ari Salinger
Favorite
Samareh Afsari, Hamid

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Hamid Samareh Afsari
Favorite
San Emeterio, Josue

Xenocs, Inc.
(T0930-01-01) Lipid Nanoparticle Morphology and Phase Transitions Investigated through Small Angle X-Ray Scattering and Contrast Variation in a Laboratory Instrument
Josue San Emeterio
Favorite
Sarsarshahi, Sina

University of Iowa
(M1030-01-04) Impact of Handling and Transfer on Aggregation of a Trastuzumab Biosimilar in an In-Use Study
Sina Sarsarshahi
Favorite
Schlender, Jan-Frederik

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Jan-Frederik Schlender
Favorite
Schmidt, Marcel

Chimera Biotec GmbH
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Marcel Schmidt
Favorite
Schrass, Leah

University of Kentucky
(M0930-02-06) Investigations into the Effects of Protein Corona Formation on Novel Polymeric Nanoparticle Systems
Leah Schrass
Favorite
Sekar, Ram Prasad

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Ram Prasad Sekar
Favorite
Sekhoacha, Mamello

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Mamello Sekhoacha
Favorite
Serre, Christian

Institut des Matériaux Poreux de Paris
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Christian Serre
Favorite
Shao, Hongguang

Frontage Laboratories, Inc.
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Hongguang Shao
Favorite
Shapiro, Irina

Cullinan Therapeutics
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Irina Shapiro
Favorite
Sharma, Puja

Teva Pharmaceutical Industries Ltd.
(T1030-01-03) ATR-FTIR Spectroscopy as an Orthogonal Method for Secondary Structure Characterization of Monoclonal Antibodies Under Thermal Stress
Puja Sharma
Favorite
Shearer, Todd

Cullinan Therapeutics
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Todd Shearer
Favorite
Sheng, Xinyi

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
Xinyi Sheng
Favorite
Shin, Young G.

ChungNam National University
(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders
Young G. Shin
Favorite
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Young G. Shin
Favorite
(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method
Young G. Shin
Favorite
(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate
Young G. Shin
Favorite
(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS
Young G. Shin
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Young G. Shin
Favorite
Shipalana, Hlurile

University of the Free State
(M1430-01-01) Nanocapsules for Combined Delivery of Docetaxel and Laguncularia Racemosa Extract Against Oral Cancer Cells In Vitro
Hlurile Shipalana
Favorite
Shi, Wenting

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
Wenting Shi
Favorite
Shouse, Lauren

Samford University
(M1030-01-05) Evaluating the Immunomodulatory Efficacy of an Ethanolic Spray-Dried Extract of Spirulina
Lauren Shouse
Favorite
Siddhanta, Kasturi

University of Nebraska Medical Center
(T1030-01-04) Development of Polymer-Based miRNA Delivery System for CXCR4 Inhibition and miR155 Inhibition in Target Cells in the Liver to Treat Alcohol-Associated Liver Disease
Kasturi Siddhanta
Favorite
Silva, Kalhari

Custom Biologics
(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Kalhari Silva
Favorite
Sinegra, Andrew

Merck & Co., Inc.
(M1330-01-01) Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Andrew Sinegra
Favorite
Singh, Vikas

Eurofins Viracor Biopharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Vikas Singh
Favorite
Sinha, Garima

Croda Inc.
(M1130-02-09) Alternative Detergents to Triton X-100 for Disrupting Lipid Nanoparticles and Enhancing RNA Encapsulation Quantification in RiboGreen Assay
Garima Sinha
Favorite
Sinko, Balint

Pion Inc.
(M1130-02-08) Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs
Balint Sinko
Favorite
Sintetas, Ashley

Eurofins Viracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Ashley Sintetas
Favorite
Solomon, Matthew

Merck & Co., Inc.
(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay
Matthew Solomon
Favorite
Song, Kent

Sanofi
(T1130-02-08) Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers
Kent Song
Favorite
Souleyrette, Caroline

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Caroline Souleyrette
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Caroline Souleyrette
Favorite
Stanta, Johannes

Celerion
(M1030-02-09) Advancing Peripheral Blood Mononuclear Cells Isolation for ELISPOT Analysis: Time Is Critical
Johannes Stanta
Favorite
(M1230-02-09) Bringing Unstable Flow Cytometry Assays Closer to the Patient: Case Study of an Ex Vivo CD11b Stimulation Flow Cytometry Assay Collected at External Clinical Site
Johannes Stanta
Favorite
Stark, Jared

KCAS Bio
(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture
Jared Stark
Favorite
Steeno, Greg

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Greg Steeno
Favorite
Stein, Andrew

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Andrew Stein
Favorite
Stevens, Scott

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Scott Stevens
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Scott Stevens
Favorite
Sun, Li

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Li Sun
Favorite
Suryanarayanan, Raj

University of Minnesota
(T1230-01-05) Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Raj Suryanarayanan
Favorite
Svilenov, Hristo

Technical University
(M1230-01-02) Additivity of Transfer Free Energies Enables Description of Complex Protein Formulations in Implicit Solvent Molecular Dynamics Simulations
Hristo Svilenov
Favorite
(M1430-01-05) Running at the Verge of Collapse in Lyophilization: What is the Impact of the Edge Vial Effect on Protein Stability and Particle Morphology?
Hristo Svilenov
Favorite
T
Tam, Susan

Tavotek Biotherapeutics
(M1430-02-06) Clinical Evidence of Safety, Prolonged Half-Life, and Low Immunogenicity of Monoclonal Antibodies TAVO101 and TAVO103 Engineered with Multiple Fc Mutations
Susan Tam
Favorite
Tao, Yali

WuXi Biologics
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Yali Tao
Favorite
Tasneem, Farzana

Surana College Autonomus
(T1030-01-05) GCMS Analysis of Bioactive Compounds of Extracted Growth Hormone Concentration (Auxin) and Antimicrobial Activity of Pentas lanceolata and Chrysanthemum Morifolium: An Ornamental Flowering Plants
Farzana Tasneem
Favorite
Tekyetim, Duygu

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Duygu Tekyetim
Favorite
Thompson, Kyle

Eurofins Viracor Biopharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Kyle Thompson
Favorite
Tian, Yu

Merck & Co., Inc.
(M1330-01-03) Engineering Extended-Release Profiles for Biologic Drugs via Chemical Crosslinking of Poloxamer 407 Hydrogels
Yu Tian
Favorite
Tong, Xinming

Genentech, Inc.
(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Xinming Tong
Favorite
Townsend, Tiffany

Purdue Global
(T1230-02-06) Fostering Innovation and Expanding Institutional Research from Bench to Bedside
Tiffany Townsend
Favorite
Tsung, Jamie

Alnylam Pharmaceuticals Inc.
(T1330-01-04) Platform Formulation Approach for Injectable GalNAc siRNA
Jamie Tsung
Favorite
(T1430-01-03) Importance of Early-Stage Process Design Space Assessment for Lipid Nanoparticles (LNP) Technology Transfer
Jamie Tsung
Favorite
Tubbs, Josiah

Celerion
(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Josiah Tubbs
Favorite
U
Uludag, Hasan

University of Alberta
(M1430-01-04) Implementing siRNA Therapy Targeted at MLL-AF4 in Acute Lymphoblastic Leukemia
Hasan Uludag
Favorite
Unger, Max

Coriolis Pharma Research GmbH
(M1230-01-02) Additivity of Transfer Free Energies Enables Description of Complex Protein Formulations in Implicit Solvent Molecular Dynamics Simulations
Max Unger
Favorite
Urlacher, Teresa

Celerion
(M1030-02-09) Advancing Peripheral Blood Mononuclear Cells Isolation for ELISPOT Analysis: Time Is Critical
Teresa Urlacher
Favorite
(M1230-02-09) Bringing Unstable Flow Cytometry Assays Closer to the Patient: Case Study of an Ex Vivo CD11b Stimulation Flow Cytometry Assay Collected at External Clinical Site
Teresa Urlacher
Favorite
V
Vallamkonda, Bhaskar

Odin Pharmaceticals LLC
(T1230-01-01) Mutagenic NDSRI of Citalopram - Critical Structural Evaluation of Carcinogenic Category and Development of a Highly Sensitive LC-MS/MS Method Development for Quantification
Bhaskar Vallamkonda
Favorite
Van De Vyver, Arthur

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Arthur Van De Vyver
Favorite
Vazvaei-Smith, Faye

Merck & Co., Inc.
(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study
Faye Vazvaei-Smith
Favorite
(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay
Faye Vazvaei-Smith
Favorite
Veeramachaneni, Rathna

KCAS Bio
(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture
Rathna Veeramachaneni
Favorite
Velankar, Ketki

Duquesne University
(T0930-01-04) Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Ketki Velankar
Favorite
Venegas Mata, Cindy

South Dakota State University
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Cindy Venegas Mata
Favorite
Vijayanand, Sharon

Mercer University
(T1430-01-01) 3-D Printed Rapidly Disintegrating Oral Films for Targeted Delivery of Aspirin in the Brain for Ischemic Stroke
Sharon Vijayanand
Favorite
Voelker, Troy

Aliri USA, Inc.
(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows
Troy Voelker
Favorite
W
Walbi, Ismail

Najran University
(T0930-01-03) Formulation and Evaluation of Silymarin Proniosomes for Enhanced Solubility, Bioavailability, and Therapeutic Efficacy
Ismail Walbi
Favorite
Walker, Dwight

Qatch Technologies
(M1030-01-03) High-Throughput Viscometry with Injectability Screening of High Concentration Protein Formulations by Multiplexed Microfluidic Quartz Resonators
Dwight Walker
Favorite
Walker, Joshua

Oregon Health and Science University
(T0930-01-02) Investigating the Effects of Multi-Drug-Loaded Nanospheres in Enhancing Antitumor Efficacy and Augmenting Immune Response Against Metastatic Melanoma
Joshua Walker
Favorite
Wang, Lixue

Binghamton University
(T1430-01-05) Rapid and Precise Detection of Mutations in Extracellular Vesicle DNA Using a Liposome-Based CRISPR-Cas12a System
Lixue Wang
Favorite
Wan, Yuan

Binghamton University
(T1430-01-05) Rapid and Precise Detection of Mutations in Extracellular Vesicle DNA Using a Liposome-Based CRISPR-Cas12a System
Yuan Wan
Favorite
Warner, April

Husson University
(T1030-01-02) Blueberry-Derived Exosomes as a Natural miRNA Delivery System for the Treatment of Neurodegenerative Diseases
April Warner
Favorite
Wei, Pu-Sheng

Binghamton University
(M1230-01-04) Engineering ‘Eat Me’ Signals for LNPs to Enhance mRNA Cancer Vaccination
Pu-Sheng Wei
Favorite
Werth, Emily

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Emily Werth
Favorite
West, Phillip

University of Tennessee
(M1430-01-03) Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Phillip West
Favorite
(T1430-01-04) Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Phillip West
Favorite
Wheeler, Grant

Colorado School of Mines
(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Grant Wheeler
Favorite
Wilcock, Brandon

Aliri Bioanalysis
(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows
Brandon Wilcock
Favorite
Wilson, Ian

Imperial College London
(M1330-02-07) Investigating Off Target Pharmacology and Metabolism of Methapyrilene Using Metabolomics, Lipidomics, and MS Imaging: A Case Study
Ian Wilson
Favorite
Wissel, Mark

Eurofins Viracor BioPharma Services
(M1030-02-06) The Importance of Pairing a Matrix with a Nucleic Acid Extraction Approach: Compilation of 66 Bioanalytical PCR (qPCR and dPCR) Validations
Mark Wissel
Favorite
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Mark Wissel
Favorite
Woo, Sung Ho

TriOar Inc.
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Sung Ho Woo
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Sung Ho Woo
Favorite
X
Xu, Tao

Frontage Laboratories, Inc.
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Tao Xu
Favorite
Y
Yang, Tianzhi

Western New England University
(T1030-01-02) Blueberry-Derived Exosomes as a Natural miRNA Delivery System for the Treatment of Neurodegenerative Diseases
Tianzhi Yang
Favorite
Yannoni, Yvonne

Cullinan Therapeutics
(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology
Yvonne Yannoni
Favorite
Yarraguntla, Srinivasa Rao

Vignan University
(T1230-01-01) Mutagenic NDSRI of Citalopram - Critical Structural Evaluation of Carcinogenic Category and Development of a Highly Sensitive LC-MS/MS Method Development for Quantification
Srinivasa Rao Yarraguntla
Favorite
Ybarra, Elijah

Eurofins VIracor BioPharma Services
(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR: A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab
Elijah Ybarra
Favorite
Ye, Nan

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Nan Ye
Favorite
Ye, Sally

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Sally Ye
Favorite
Ye, Stan

Novartis
(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Stan Ye
Favorite
Ying, Xi

Georgia Institute of Technology
(T1330-01-02) Optimizing Gel Network Architecture for Oxanorbornadiene-Based Degradable Hydrogels
Xi Ying
Favorite
Younes, Husam

Qatar University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Husam Younes
Favorite
You, Zhiping

Pfizer Inc.
(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma
Zhiping You
Favorite
Yu, Mathilde

Cerba Research
(T1130-02-07) Mitigation of the Presence of Crosstalk in an ADA Bridging Assay Using the MSD Platform for the Detection of Antibodies against an Antibody-Drug Conjugate
Mathilde Yu
Favorite
Yun, Sang Hyeon

TriOar Inc.
(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery
Sang Hyeon Yun
Favorite
(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS
Sang Hyeon Yun
Favorite
Yu, Yanjiao

Tavotek Biotherapeutics
(T1330-02-09) Preliminary Phase 1a Clinical Results of Multispecific Antibody TAVO412 in Patients with Hard-to-Treat Solid Tumors
Yanjiao Yu
Favorite
Yu, Zhihao

Institut des Matériaux Poreux de Paris
(M0930-01-02) Exploring the Impact of Iron Availability on Morphology and Antibiotic Resistance in Mycobacterium Species
Zhihao Yu
Favorite
Z
Zaslavskaia, Lioudmila

Boehringer Ingelheim
(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Lioudmila Zaslavskaia
Favorite
Zhang, Di

Tavotek Biotherapeutics
(M1430-02-06) Clinical Evidence of Safety, Prolonged Half-Life, and Low Immunogenicity of Monoclonal Antibodies TAVO101 and TAVO103 Engineered with Multiple Fc Mutations
Di Zhang
Favorite
Zhang, Wei

Tavotek Biotherapeutics
(T1330-02-09) Preliminary Phase 1a Clinical Results of Multispecific Antibody TAVO412 in Patients with Hard-to-Treat Solid Tumors
Wei Zhang
Favorite
Zhao, Zhixin

WuXi Biologics
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Zhixin Zhao
Favorite
Zhou, Yuan

WuXi Biologics
(T1230-01-03) Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Yuan Zhou
Favorite
Zhu, Ying

Kingston University
(M1430-01-02) Revolutionizing Ocular Drug Delivery: Prolonged Sunitinib Release from Elastomeric Biodegradable Injectable Tiny Implants for Treatment of Diabetic Retinopathy
Ying Zhu
Favorite
Zuluaga-Rave, David

Resolian Inc.
(T1430-02-08) A Sensitive, Specific and High-throughput Assay to Quantify an Oligonucleotide Therapeutics in Monkey Liver using Stem‑Loop RT-qPCR Platform
David Zuluaga-Rave
Favorite